The drugmaker Eli Lilly this week said that tests of its GLP-1 pill could work just as well as injectable drugs like ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent years, hailed as revolutionary ...

Massachusetts' largest commercial health insurer is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for ...

A new weight-loss pill taken daily could compete with injections like Ozempic, new research suggests. Patients, who all were ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

If approved for wide release, the pill, orforglipron, could shake up the booming GLP-1 market by offering an option that's easier to make and store than the injections that are currently available.